EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study

Raffaele Napoli iD, Antonio Nicolucci iD, Monica Larosa, Maria Chiara Rossi iD, Riccardo Candido, RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15697 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Raffaele Napoli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, Unit of Precision Internal Medicine, Federico II University School of Medicine and Institute of Experim…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glycated Hemoglobin, Insulin Glargine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the effectiveness of different basal insulins (BI) prescribed as an add‐on to or switch from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy. Materials and Methods Retrospective, real‐world data from electronic medical records of 32 Italian diabetes clinics were used, after propensity score adjustment, to compare effectiveness after 6 months of treatment with second‐ versus first‐generation BI (2BI vs. 1BI) or glargine 300 U/ml versus degludec 100 U/ml (Gla‐300 vs. Deg‐100), when added to (ADD‐ON) or in substitution of (SWITCH) GLP‐1 RA. Only comparisons, including a minimum of 100 patients per group, were performed to ensure adequate robustness of the analyses.

Results

In the ADD‐ON cohort (N = 700), greater benefits of 2BI versus 1BI were found in glycated haemoglobin {HbA1c; estimated mean difference: −0.32% [95% confidence interval (CI) −0.62; −0.02]; p = .04} and fasting blood glucose [FBG; −20.73 mg/dl (95% CI −35.62; −5.84); p = .007]. In the SWITCH cohort (N = 2097), greater benefits of 2BI versus 1BI were found in HbA1c [−0.22% (95% CI −0.42; −0.02); p = .03], FBG [−10.15 mg/dl (95% CI −19.04; −1.26); p = .03], and body weight [−0.67 kg (95% CI −1.30; −0.04); p = .04]. In the SWITCH cohort starting 2BI (N = 688), marked differences in favour of Gla‐300 versus Deg‐100 were documented in HbA1c [−0.89% (95% CI −1.26; −0.52); p < .001] and FBG [−17.89 mg/dl (95% CI −32.45; −3.33); p = .02]. Using propensity score matching as a sensitivity analysis, the benefit on HbA1c was confirmed [−0.55% (95% CI –1.02; −0.08); p = .02]. BI titration was suboptimal in all examined cohorts.

Conclusions

2BI are a valuable option to intensify GLP‐1 RA therapy. Switching to Gla‐300 versus Deg‐100 was associated with greater HbA1c improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsGlycated HemoglobinInsulin GlargineInsulin, Long-ActingGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedBlood GlucoseDrug Therapy, CombinationItalyTreatment OutcomeComparative Effectiveness ResearchDrug SubstitutionHypoglycemia

Stichwörter der Autor:innen

basal insulindegludec 100 U/mleffectivenessfixed‐ratio combinationglargine 300 U/mlglucagon‐like peptide‐1 receptor agonistsinsulin naïvesafetytype 2 diabetes

Substanzen

Hypoglycemic AgentsGlycated HemoglobinInsulin GlargineInsulin, Long-ActingBlood Glucosehemoglobin A1c protein, humaninsulin degludecGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Translational Medical Sciences, Unit of Precision Internal Medicine, Federico II University School of Medicine and Institute of Experimental Endocrinology and Oncology, National Research Council, Naples, I…
  • CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
  • Medical Affairs, Sanofi S.r.l., Milan, Italy.
  • Diabetes Centre District 3, Azienda Sanitaria Universitaria Integrata, Trieste, Italy.

ORCID-Profile: Raffaele Napoli, Antonio Nicolucci, Maria Chiara Rossi

Zitieren

APA

Napoli, R., Nicolucci, A., Larosa, M., Rossi, M. C., Candido, R., & RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group (2024). Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15697

Vancouver

Napoli R, Nicolucci A, Larosa M, Rossi MC, Candido R, RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group. Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15697

BibTeX
@article{Napoli2024,
  author = {Napoli, Raffaele and Nicolucci, Antonio and Larosa, Monica and Rossi, Maria Chiara and Candido, Riccardo and RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group, RESTORE‐G (Retrospective analysis on the therapeutic approaches after GLP‐1 RA treatment in type 2 diabetes patients) Study Group},
  title = {Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15697}
}
Kostenlos starten →